文献速递主动脉疾病

胸主动脉腔内修复术治疗B型急性主动脉夹层合并降主动脉瘤

Thoracic Endovascular Aortic Repair for Type B Acute Aortic Dissection Complicated by Descending Thoracic Aneurysm.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2017-03-22

院内TEVAR相关死亡率为14%,1年生存率82%,5年生存率64%。作者认为TEVAR在高危队列中结果满意,优于开放手术风险评分预测。

要点

  • B型急性主动脉夹层起病即可合并降主动脉瘤,平均主动脉直径66±26 mm。
  • TEVAR院内相关死亡率14%,随访期TEVAR相关死亡率5%。
  • 1年及5年生存率分别为82%和64%,5年免于再干预率77%。

核心结论

  • 在B型急性主动脉夹层合并降主动脉瘤的高危队列中,TEVAR结果满意,优于开放手术风险评分预测。
  • 随访期间主动脉直径稳定,无主动脉相关不良事件。

研究设计与样本

  • 纳入标准包括降主动脉瘤≥50 mm、已知动脉瘤样降主动脉上发生夹层、或总直径<50 mm但较既往CTA非夹层主动脉直径增加>50%。
  • 主要终点为早期和长期生存、免于TEVAR及主动脉相关死亡、免于再干预。

主要发现

  • 平均主动脉直径为66±26 mm(范围42-130;IQR 51-64)。
  • 院内TEVAR相关死亡率为14%(n=3)。
  • 随访期间累积死亡率为26%(n=5),TEVAR相关死亡率为5%(n=1)。
  • 总体生存率估计1年为82%(95%CI:61.5-93),5年为64%。
  • 持续主要临床成功率为79%(再干预n=4);免于主动脉相关死亡1年和5年均为86%(95%CI:66-95);免于再干预1年为95%(95%CI:75.5-95),5年为77%(95%CI:50-92)。

临床怎么用

  • 对于B型急性主动脉夹层合并降主动脉瘤的高危患者,TEVAR可作为治疗选择。
  • 需关注院内TEVAR相关死亡风险及随访期再干预可能。

局限性

  • 随访时间变异较大(平均56±45个月,范围6-149个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyse the results and review the literature about thoracic aortic endovascular repair (TEVAR) for type B acute aortic dissection (TBAAD) complicated by descending thoracic aortic aneurysm (DTA) in the hyperacute or acute phases. METHODS: This was a multicentre, observational descriptive study. Inclusion criteria were TBAAD with a DTA of ≥50 mm, TBAAD on an already known aneurysmal descending thoracic aorta, and TBAAD presenting with an enlarged aorta with a total diameter <50 mm, but with >50% diameter increase compared with a previous computed tomography angiography (CTA) showing a non-dissected aorta with normal sizing. Primary endpoints were early and long-term survival, freedom from TEVAR and aortic related mortality (ARM), and freedom from re-intervention. RESULTS: Twenty-two patients were included in the analysis. The mean aortic diameter was 66 ± 26 mm (range 42-130; IQR 51-64). The in hospital TEVAR related mortality was 14% (n = 3). The mean radiological follow-up was 56 ± 45 months (range 6-149; IQR 12-82), and the follow-up index 0.97 ± 0.1. All surviving patients were available for follow-up. During follow-up the cumulative mortality was 26% (n = 5) and TEVAR related mortality was 5% (n = 1). Overall the estimate of survival was 82% (95%CI: 61.5-93) at 1 year, and 64% at 5 years. Ongoing primary clinical success was 79% (re-intervention n = 4). Freedom from aortic related mortality was 86% (95%CI: 66-95) at 1 and 5 year, while freedom from re-intervention was 95% (95%CI: 75.5-95) at 1 year, and 77% (95%CI: 50-92) at 5 years. CONCLUSIONS: In our experience, DTA is a frequent complication from the very beginning of the clinical onset of TBAAD. In this high-risk cohort, TEVAR showed satisfactory results, better than those predicted by the risk score for open repair, with favourable stability of the aortic diameter and no aortic related adverse events during follow-up.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Piffaretti G, Ottavi P, Lomazzi C, et al. Thoracic Endovascular Aortic Repair for Type B Acute Aortic Dissection Complicated by Descending Thoracic Aneurysm. Eur J Vasc Endovasc Surg. 2017. PMID: 28341530. doi:10.1016/j.ejvs.2017.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。